Ultimovacs - Gathering steam with multiple inflections in FY23
Ultimovacs' Q422 and FY22 results reflected another busy period marked by continued development of its lead cancer vaccine, UV1, across multiple indications. Top-line results from the Phase II clinical
Source: finanznachrichten.de